|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2003-6-6
|
|
pubmed:abstractText |
Invasive pulmonary aspergillosis is an important cause of morbidity and mortality in immunocompromised patients. Simultaneous inhibition of fungal cell-wall and cell-membrane biosynthesis may result in synergistic interaction against Aspergillus fumigatus. We studied the antifungal activity of micafungin, a new echinocandin, in combination with ravuconazole, a second-generation triazole, against experimental invasive pulmonary aspergillosis in persistently neutropenic rabbits. This combination led to significant reductions in mortality (P</=.001), residual fungal burden (P</=.05), and serum galactomannan antigenemia (P</=.01), compared with either agent alone. Combination therapy also resulted in reduction (P</=.05) of organism-mediated pulmonary injury and of pulmonary infiltrates detected by thoracic computed tomography (P</=.001). No toxicity was observed with the echinocandin-triazole combination. An MTT hyphal damage assay demonstrated significant in vitro synergistic interaction between the antifungal triazole and the echinocandin. The combination of an antifungal triazole and echinocandin may represent a new strategy for treatment of invasive pulmonary aspergillosis.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0022-1899
|
|
pubmed:author |
pubmed-author:AvilaNilo ANA,
pubmed-author:BacherJohnJ,
pubmed-author:CaslerHeather EHE,
pubmed-author:GrollAndreas HAH,
pubmed-author:KelaherAmy MAM,
pubmed-author:LymanCaron ACA,
pubmed-author:PetraitieneRutaR,
pubmed-author:PetraitisVidmantasV,
pubmed-author:SarafandiAlia AAA,
pubmed-author:SeinTinT,
pubmed-author:WalshThomas JTJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
187
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1834-43
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:12792859-Animals,
pubmed-meshheading:12792859-Aspergillosis,
pubmed-meshheading:12792859-Aspergillus fumigatus,
pubmed-meshheading:12792859-Disease Models, Animal,
pubmed-meshheading:12792859-Drug Synergism,
pubmed-meshheading:12792859-Drug Therapy, Combination,
pubmed-meshheading:12792859-Echinocandins,
pubmed-meshheading:12792859-Female,
pubmed-meshheading:12792859-Lipopeptides,
pubmed-meshheading:12792859-Lipoproteins,
pubmed-meshheading:12792859-Lung,
pubmed-meshheading:12792859-Lung Diseases, Fungal,
pubmed-meshheading:12792859-Organ Size,
pubmed-meshheading:12792859-Peptides, Cyclic,
pubmed-meshheading:12792859-Rabbits,
pubmed-meshheading:12792859-Thiazoles,
pubmed-meshheading:12792859-Triazoles
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin.
|
|
pubmed:affiliation |
Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
|
|
pubmed:publicationType |
Journal Article
|
